Silexion Therapeutics
Silexion Therapeutics is a biotechnology company that focuses on developing treatments for KRAS-driven cancers. The company's lead product, SIL-204, is a small interfering RNA (siRNA) therapy in an extended-release formulation for the treatment of locally advanced pancreatic cancer. Silexion offers its clinical-stage oncology platform with plans for further trials to improve treatment outcomes for patients with specific KRAS mutations.
Domain
silexion.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$6.0M
Founded
2007
No technologies detected yet for this company.
Frequently Asked Questions
What technologies does Silexion Therapeutics use?+
We have not yet detected technologies for Silexion Therapeutics.
What industry is Silexion Therapeutics in?+
Silexion Therapeutics operates in the Biotechnology industry.
Where is Silexion Therapeutics based?+
Silexion Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026